ISRCTN25003627已完成未知
A study to test whether spironolactone and dietary nitrate (as beetroot juice) (I) compared to controls, alter blood vessel function, measured as the cardiac-ankle vascular index (O) or as arterial pulse wave velocity (O) in Type 2 diabetes (P): a randomised trial
King's College London (UK)0 个研究点目标入组 126 人开始时间: 2013年1月31日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 126
研究概览
简要总结
2017 Abstract results in https://www.ncbi.nlm.nih.gov/pubmed/28935045 abstract (added 04/06/2019) 2020 Results article in https://pubmed.ncbi.nlm.nih.gov/31833569/ (added 24/06/2021) 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33982797/ (added 11/03/2022)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Anyone (male or female, age 18-80) with ?diagnosed? type 2 Diabetes or at risk of type 2 Diabetes (being overweight BMI >= 27 kg/m2) or found to have impaired glucose tolerance by fasting glycaemia or by glucose tolerance testing will be eligible. Please see under exclusion criteria for limits to this
- •2. Participants need to be able to understand the protocol and be willing to comply with it
排除标准
- •1. Ongoing (chronic) illness of any type interfering with patient ability to participate
- •2. Major complications restricting mobility including active foot ulceration or amputation may be exclusion criteria, but only if the patient feels they cannot manage
- •3. Previous adverse reactions to Spironolactone or Doxazosin. (If patients are already on either of these, we can discuss alternatives)
- •4. Renal function by eGFR < 45 mls per minute (approximately - i.e. if one test is around 43 and another is around 46 the average of around 45 is acceptable)
- •5. Objective renal function tests for creatinine > 180 umol/l (when eGFR will be < 45 mls/ min).
- •6. All other aspects of diabetic control will be acceptable except gross disturbances of glycaemia with HbA1c > 11% and fasting random glucose > 12mmol/l. Those will not be indications to withdraw patients, but only as exclusions for entry (& once improved can become eligible).
- •7. For women: being pregnant or breastfeeding for the duration of the study
研究者
相似试验
已完成
不适用
combination therapy trial in COVID-19 patientsCOVID19.COVID-19, virus identifiedU07.1IRCT20201003048904N2Boushehr University of Medical Sciences200
已完成
1 期
Evaluation of CLP With and Without Spironolactone in Heart Failure Patients With Chronic Kidney DiseaseHeart FailureNCT01598740Sorbent Therapeutics18
Unknown
3 期
Spironolactone on Acute Kidney Injury in Critically Ill PatientsAcute Kidney InjuryNCT03206658Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran90
已完成
1 期
Spironolactone Combined With Captopril and Carvedilol for the Treatment of Pulmonary Arterial HypertensionHypertension, PulmonaryNCT00240656Hebei Medical University
终止
1 期
Comparison of Laboratory Changes, Food Intake and Metabolic Profile in Patients With Obesity and Type2 Diabetes Mellitus: Before, During and After Taking AphoelineBrakeDiabetes Mellitus, Type 2NCT02791867Dasman Diabetes Institute48
